<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980599</url>
  </required_header>
  <id_info>
    <org_study_id>ZBao</org_study_id>
    <nct_id>NCT04980599</nct_id>
  </id_info>
  <brief_title>Effect of a Probiotic Strain Lactobacillus Paracasei K56 on Metabolic Symptom - a Pilot Study</brief_title>
  <official_title>Effect of a Probiotic Strain Lactobacillus Paracasei K56 on Metabolic Symptom - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inner Mongolia Yili Industrial Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data suggest that gut microbiota can function as an environmental factor that&#xD;
      modulates the amount of body fat and obese individuals have an altered gut microbiota.The&#xD;
      results of previous animal studies have suggest that a probiotic strain Lactobacillus&#xD;
      paracasei K56 have reduced high-fat diet induced obesity.&#xD;
&#xD;
      In this before-after pilot study, the participants were randomly assigned to 8 groups to&#xD;
      compare the fat-reducing effect of the Lactobacillus paracasei K56 by continuously&#xD;
      supplementing different product prototypes , and screen the best probiotic K56 prototype with&#xD;
      the effect of fat reduction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percent body fat</measure>
    <time_frame>60days</time_frame>
    <description>percent body fat (%) will be assessed at baseline and after 60days of intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visceral fat area</measure>
    <time_frame>60days</time_frame>
    <description>visceral fat area (cm^2) will be assessed at baseline and after 60days of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid Profile</measure>
    <time_frame>60 days</time_frame>
    <description>Serum total cholesterol(mmol/L)，Serum triglycerides(mmol/L)，Low-density lipoprotein(mmol/L)，High density lipoprotein(mmol/L) will be measured at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>60 days</time_frame>
    <description>fasting blood glucose(mmol/L) will be measured at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>60 days</time_frame>
    <description>Glycated hemoglobin(%) will be measured at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated albumin</measure>
    <time_frame>60 days</time_frame>
    <description>Glycosylated albumin(%) will be measured at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skeletal muscle mass</measure>
    <time_frame>60 days</time_frame>
    <description>skeletal muscle mass (kg) will be assessed at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist to hip ratio (WHR)</measure>
    <time_frame>60 days</time_frame>
    <description>waist to hip ratio (WHR) will be assessed at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index BMI</measure>
    <time_frame>60 days</time_frame>
    <description>Body Mass Index (kg/m^2) will be assessed at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>60 days</time_frame>
    <description>Body weight (kg) will be assessed at baseline and after 60days of intervention</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Obesity</condition>
  <condition>Adiposity</condition>
  <arm_group>
    <arm_group_label>K56 very high dose -E1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic drink (lactobacillus paracasei K56 10^11CFU) 350ml/d , for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control -E2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin powder 1.5g/sachet , 3g/d for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 high dose-E3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10^10cfu) , for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 middle dose-E5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10^9cfu) , for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 low dose -E7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10^7cfu) , for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 middle dose-E9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^9cfu) ,for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 high dose-E1K</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^10cfu), for 60days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K56 very high dose-E11</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10^11cfu) ,for 60days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic drink with Lactobacillus paracasei K56</intervention_name>
    <description>Probiotic drink (K56 10^11CFU) 350ml/d for 60days</description>
    <arm_group_label>K56 very high dose -E1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrin powder</intervention_name>
    <description>maltodextrin powder 3g/d ,for 60days</description>
    <arm_group_label>control -E2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic powder E3</intervention_name>
    <description>Probiotic powder 3.0g/d (K56 10^10cfu) 60days;</description>
    <arm_group_label>K56 high dose-E3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic powder E5</intervention_name>
    <description>probiotic powder 8g/day for 60days</description>
    <arm_group_label>K56 middle dose-E5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic capsule E7</intervention_name>
    <description>probiotic k56 capsule, 2capsules/d (10^7cfu) for 60days</description>
    <arm_group_label>K56 low dose -E7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic capsule E9</intervention_name>
    <description>probiotic k56 capsule, 2capsules/d (10^9cfu) for 60days</description>
    <arm_group_label>K56 middle dose-E9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic capsule E10</intervention_name>
    <description>probiotic k56 capsule, 2capsules/d (10^10cfu) for 60days</description>
    <arm_group_label>K56 high dose-E1K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic capsule E11</intervention_name>
    <description>probiotic k56 capsule, 4capsules/d (10^11cfu) for 60days</description>
    <arm_group_label>K56 very high dose-E11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI&gt;=30kg/m2,or percent of body fat(PBF) &gt;=25% for male, &gt;=30 for female.&#xD;
&#xD;
          -  Age: 18 - 60 years old adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with severe chronic diseases (coronary heart disease, diabetes, hypertension,&#xD;
             immune deficiency, mental disorders, tumors, liver and kidney dysfunction, etc.) and&#xD;
             complications;irritable bowel syndrome&#xD;
&#xD;
          -  History of intervention with fat-reducing drugs or health products in the past 2&#xD;
             months&#xD;
&#xD;
          -  take weight control measures (diet, exercise, etc.) within the past month&#xD;
&#xD;
          -  Those who cannot guarantee to maintain their current lifestyle during the trial period&#xD;
&#xD;
          -  Those who fail to consume the tested samples as required, or fail to follow up on&#xD;
             time, resulting in failure to determine the efficacy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Feng, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Hua Dong Hospita Affiliated to Fu Dan University, Shanghai,China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hua Dong Hospital Affiliated to Fu Dan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhijun Bao</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>lactobacillus paracasei</keyword>
  <keyword>body fat</keyword>
  <keyword>visceral fat area</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

